New York, NY – Dr. Toshikazu Kamiya, formerly director of Kyowa Hakko Bio, Healthcare Products Development Center in Tsukuba, Japan, has joined Kyowa Hakko USA as president and chief executive officer.
Since 1997, Dr. Kamiya has been the head of the Nutraceuticals Research Group devoting himself to health care research to clarify how amino acids and other nutritional molecules relate to aging, diseases, skin disorders, obesity, and other health issues.
He received his Ph.D. in agricultural chemistry from the University of Tokyo and has worked on pharmaceutical and nutraceutical research for over 20 years at Kyowa Hakko Bio Co., Ltd.
Dr. Kamiya's background also includes experience studying the mechanisms of diabetic complications at the National Eye Institute, National Institutes of Health from 1994 to 1996.
His continuous interest in research has expanded to collaboration with prestigious research facilities including Harvard University, Penn State Medical Center and Emory University.
Kyowa Hakko Bio is the maker of leading branded ingredients including Cognizin® Citicoline, Hydrafend™ Hyaluronic Acid, Lumistor® L-Hydroxyproline, Kyowa CoQ10®, Setria® Glutathione and Sustamine™ Alanyl Glutamine. Kyowa Hakko USA offers manufacturers and formulators one of the industry's most extensive lines of over 50 amino acids and related compounds, including D-Amino acids and branch-chain amino acids, as well as nucleic acids, bio-products and fine chemicals.